Interferon-α-2b/interleukin-2
1
Reactions 562 - 5 Aug 1995 S Interferon-α-2b/interleukin-2 Glomerulonephritis in an elderly patient: case report A 66-year-old man developed pauci-immune crescentic glomerulonephritis with rapidly progressive renal failure after receiving combination therapy with interleukin-2 and interferon-α-2b for metastatic renal cell carcinoma. The man received a 4-week cycle of interleukin-2 at a dosage of 5 × 10 6 IU/m 2 8-hourly for 3 doses, then each day, for 5 days each week, in addition to interferon-α-2b 5 × 10 6 IU/m 2 for 3 days each week. After a 2-week break, the 4-week treatment cycle was repeated. On day 103, the man was admitted with renal failure and prednisone was started. He was discharged after 6 days: at this time his BUN level was elevated to 27.5 mmol/L and his serum creatinine level was 477.4 µmol/L. Seven days later, his serum creatinine level had decreased to 274 µmol/L and remained stable for approximately 6 weeks, but then increased again after prednisone was tapered; persistent haematuria was also noted. A renal biopsy revealed a crescentic glomerulonephritis without immune deposits. Prednisone was discontinued and the man’s serum creatinine level continued to rise. He declined further cancer therapy. Five months after renal biopsy, he began haemodialysis. However, he developed progressive cachexia, withdrew from haemodialysis and subsequently died. Author comment: Glomerulonephritis has previously been reported after treatment with interferon-α and interleukin-2. However, this is the first report of pauci-immune glomerulonephritis after treatment with interleukin-2 and interferon-α-2b. Parker MG, et al. Rapidly progressive glomerulonephritis after immunotherapy for cancer. Journal of the American Society of Nephrology 5: 1740-1744, Apr 1995 - USA 807076343 1 Reactions 5 Aug 1995 No. 562 0114-9954/10/0562-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Transcript of Interferon-α-2b/interleukin-2
Reactions 562 - 5 Aug 1995
SInterferon-α-2b/interleukin-2
Glomerulonephritis in an elderly patient: case reportA 66-year-old man developed pauci-immune crescentic
glomerulonephritis with rapidly progressive renal failure afterreceiving combination therapy with interleukin-2 andinterferon-α-2b for metastatic renal cell carcinoma.
The man received a 4-week cycle of interleukin-2 at a dosageof 5 × 106 IU/m2 8-hourly for 3 doses, then each day, for 5 dayseach week, in addition to interferon-α-2b 5 × 106 IU/m2 for 3days each week. After a 2-week break, the 4-week treatmentcycle was repeated.
On day 103, the man was admitted with renal failure andprednisone was started. He was discharged after 6 days: at thistime his BUN level was elevated to 27.5 mmol/L and his serumcreatinine level was 477.4 µmol/L. Seven days later, his serumcreatinine level had decreased to 274 µmol/L and remainedstable for approximately 6 weeks, but then increased againafter prednisone was tapered; persistent haematuria was alsonoted.
A renal biopsy revealed a crescentic glomerulonephritiswithout immune deposits.
Prednisone was discontinued and the man’s serumcreatinine level continued to rise. He declined further cancertherapy. Five months after renal biopsy, he beganhaemodialysis. However, he developed progressive cachexia,withdrew from haemodialysis and subsequently died.
Author comment: Glomerulonephritis has previously beenreported after treatment with interferon-α and interleukin-2.However, this is the first report of pauci-immuneglomerulonephritis after treatment with interleukin-2 andinterferon-α-2b.Parker MG, et al. Rapidly progressive glomerulonephritis after immunotherapy forcancer. Journal of the American Society of Nephrology 5: 1740-1744, Apr 1995 -USA 807076343
1
Reactions 5 Aug 1995 No. 5620114-9954/10/0562-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
